J. Tuttle

发表

Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.

P. Verhoest, A. Dounay, J. Tuttle, 2015, Journal of medicinal chemistry.

Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics

J. Pandit, R. Obach, Ji-Young Kim, 2013 .

PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.

J. Pandit, Ji-Young Kim, P. Verhoest, 2013, Bioorganic & medicinal chemistry letters.

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

K. Gajiwala, A. Kalgutkar, P. Verhoest, 2021, Science.

Fingolimod (Gilenya): The First Oral Treatment for Multiple Sclerosis

J. Tuttle, C. Ende, 2015 .

Enantioselective organocatalytic hydride reduction.

D. MacMillan, S. Ouellet, J. Tuttle, 2005, Journal of the American Chemical Society.

Organocatalytic transfer hydrogenation of cyclic enones.

D. MacMillan, S. Ouellet, J. Tuttle, 2006, Journal of the American Chemical Society.

Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.

F. Menniti, F. Nelson, C. Proulx-Lafrance, 2012, Journal of medicinal chemistry.

A general strategy for the synthesis of cyclic N-aryl hydroxamic acids via partial nitro group reduction.

Ji-Young Kim, P. Verhoest, Laura A McAllister, 2011, The Journal of organic chemistry.

Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions.

J. Pandit, Ji-Young Kim, P. Verhoest, 2013, ACS medicinal chemistry letters.

Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition

K. A. Welch, T. Maurer, P. Verhoest, 2018, Molecular Pharmacology.

Synthesis of ortho-substituted nitroaromatics via improved Negishi coupling conditions

Ji-Young Kim, P. Verhoest, Jaclyn L Henderson, 2011 .

Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia.

J. Pandit, Ji-Young Kim, M. Hayward, 2012, ACS medicinal chemistry letters.

Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoE.

P. Verhoest, C. Steppan, Travis T Wager, 2020, Cell chemical biology.

The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia

B. L. Kormos, J. Tuttle, 2014 .

Selective Brain Penetrant PDE 9 A Inhibitor for the Treatment of Cognitive Disorders

Ey, F. Menniti, F. Nelson, 2012 .

Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.

J. Cianfrogna, A. Stepan, Daniel P. Walker, 2014, Journal of medicinal chemistry.

Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates.

J. Cianfrogna, A. Stepan, Daniel P. Walker, 2017, Journal of medicinal chemistry.

An inverse agonist of orphan receptor GPR61 acts by a G protein-competitive allosteric mechanism

Yuan Zhang, B. L. Kormos, R. Unwalla, 2023, Nature communications.

Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.

P. Verhoest, A. Dounay, J. Tuttle, 2015, Journal of medicinal chemistry.

Highly Potent , Selective , and E ffi cacious Metabotropic Glutamate Receptor 5 ( mGluR 5 ) Negative Allosteric Modulator

Ey, J. Cianfrogna, A. Stepan, 2014 .